Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus
Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus
复制标题
DOI：
10.1136/jcp.2007.054304
复制
发表时间：
2008-09-01
影响因子：
3.4
通讯作者：
Kilpatrick, E. S.
中科院分区：
文献类型：
--
作者：
Kilpatrick, E. S.
血红蛋白A（1c）（HbA（1c））即将迎来40岁生日。许多人会认为，在20多岁时进行的与糖尿病并发症相关的临床研究可能是其有史以来最好的成就。然而，这篇文章着眼于HbA（1c）是如何从那时起成熟的，并详细讨论了它的许多优势和特质作为一个30多岁的人，作为一个高血糖风险的标志，变得更加清楚。随着HbA（1c）接近中年，本文还描述了该测试似乎正在发展中年危机，因为关于如何表达其结果的争论似乎可能会在未来一段时间内在临床医生中产生分歧。
Haemoglobin A(1c) (HbA(1c)) is due to celebrate its 40th birthday. Many people would argue that the clinical studies relating the test to diabetes complications while in its late 20s are likely to be its finest ever achievement. However, this article looks at how HbA(1c) has matured since then and discusses in detail how its many strengths and idiosyncrasies as a marker of glycaemic risk have, as a 30-something, become more clearly understood. As HbA(1c) approaches middle age, this paper also describes how the test appears to be developing a mid-life crisis, as debate over how its results should be expressed seems likely to divide opinion among clinicians for some time to come.